Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:02:37.168Z.
Consensus retrieved: 2026-10-06T14:03:12.210Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:02:37.168Z.
Quote observation: 2026-10-06T19:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 65e01e2061821370315a71c231e2ba412a336584d38d2dbcbde0d0d1c3e2cd16
Forward PE Ratio (N/A) = Dated Quote Price ($8.99) / Consensus Forward EPS ($-2.95)
FORWARD PE RATIO
N/A
Mobia Medical, Inc. Common Stock
Market Cap
$299.07M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $299.07M | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $292.95M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $288.77M | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $306.96M | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.56M | N/A |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.67M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.62M | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.77M | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A |
| Standard BioTools Inc. (LAB)vs › | $281.89M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $8.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.95 | $-3.55 – $-2.35 | 3 | n/m |
| 2027-12-31 | $-2.20 | $-2.30 – $-2.11 | 3 | n/m |
| 2028-12-31 | $-2.19 | $-2.33 – $-2.05 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
